![]() |
|
|
#3 |
|
Proud Canadian Citizen
|
..that the Phase 2B trial results for its drug, AOD9604, do not support the commercial viability of the drug as a treatment for obesity. Development of the drug for this condition is terminated.
Trial results showed that weight loss compared to placebo at the primary and secondary endpoints of 12 or 24 weeks of treatment, was too low to reach statistical significance. The design of the obesity trial included Phase 3 conditions, such as a broader population of subjects (536 in total) and a formal diet and exercise programme. Under these additional conditions the AOD9604 treatment did not demonstrate the weight loss required to support commercial outcomes.... |
|
|
|
![]() |
| Thread Tools | |
| Display Modes | |
|
|